Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
EDITOR,--The meta-analysis by I M Anderson and B M Tomenson is an interesting development in the literature addressing the effectiveness and cost effectiveness of prescribing of antidepressants.1 The authors estimate that the risk of patients stopping treatment is 10% lower with selective serotonin reuptake inhibitors than tricyclic antidepressants. They note, however, that this corresponds to an absolute reduction in the total drop out rate of only 2.5% (their table IV) and is of borderline significance. Also, as they suggest, biases such as "patient selection, previous treatment, methodology, and study setting" may exist and make this result unreliable.
Unfortunately, although this is an apparently carefully constructed and methodologically sound paper, the results are presented misleadingly in the abstract, which states that "the total discontinuation rate was 10% lower with selective serotonin reuptake inhibitors than with tricyclic antidepressants...and the drop out rate due
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?